Literature DB >> 19281538

Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity.

Z Hasan1, B Jamil, J Khan, R Ali, M A Khan, N Nasir, M S Yusuf, S Jamil, M Irfan, R Hussain.   

Abstract

Protection against Mycobacterium tuberculosis infection is dependent on T cell and macrophage activation regulated by cytokines. Cytokines and chemokines produced at disease sites may be released into circulation. Data available on circulating cytokines in tuberculosis (TB) is mostly on pulmonary TB (PTB) with limited information on extrapulmonary disease (EPul-TB). We measured interferon-gamma (IFN-gamma), interkeukin-10 (IL-10), CXCL9 and CCL2 in sera of patients (n = 80) including; PTB (n = 42), EPul-TB (n = 38) and BCG vaccinated healthy endemic controls (EC, n = 42). EPul-TB patients comprised those with less severe (LNTB) or severe (SevTB) disease. Serum IFN-gamma, IL-10 and CXCL9 levels were significantly greater while CCL2 was reduced in TB patients as compared with EC. IFN-gamma was significantly greater in PTB as compared with LNTB (P = 0.002) and SevTB (P = 0.029). CXCL9 was greater in PTB as compared with LNTB (P = 0.009). In contrast, CCL2 levels were reduced in PTB as compared with LNTB (P = 0.021) and SevTB (P = 0.024). A Spearman's rank correlation analysis determined a positive association between IFN-gamma and IL-10 (rho = 0.473, P = 0.002) and IFN-gamma and CXCL9 (rho = 0.403, P = 0.008) in the PTB group. However, in SevTB, only IFN-gamma and CXCL9 were positively associated (rho = 0.529, P = 0.016). Systemic levels of cytokines are reflective of local responses at disease sites. Therefore, our data suggests that in PTB increased IFN-gamma and CXCL9 balanced by IL-10 may result in a more effective cell mediated response in the host. However, elevated inflammatory chemokines CXCL9 and CCL2 in severe EPul-TB without concomitant down modulatory cytokines may exacerbate disease related pathology and hamper restriction of M. tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19281538     DOI: 10.1111/j.1365-3083.2008.02217.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  26 in total

1.  Extra-pulmonary tuberculosis: a biomarker analysis.

Authors:  J Fortún; P Martín-Dávila; E Gómez-Mampaso; A Vallejo; C Cuartero; A González-García; J Rubí; E Pallarés; S Moreno
Journal:  Infection       Date:  2014-03-21       Impact factor: 3.553

2.  Endogenously activated interleukin-4 differentiates disease progressors and non-progressors in tuberculosis susceptible families: a 2-year biomarkers follow-up study.

Authors:  Rabia Hussain; Najeeha Talat; Ambreen Ansari; Firdaus Shahid; Zahra Hasan; Ghaffar Dawood
Journal:  J Clin Immunol       Date:  2011-07-14       Impact factor: 8.317

3.  Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Kebatshabile Nfanyana; Scarlett L Bellamy; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  Lancet Infect Dis       Date:  2015-02-09       Impact factor: 25.071

4.  Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease.

Authors:  S-Y Kim; W-J Koh; H Y Park; K Jeon; O J Kwon; S-N Cho; S J Shin
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

5.  Lateral flow assay for simultaneous detection of cellular- and humoral immune responses.

Authors:  Paul L A M Corstjens; Claudia J de Dood; Jolien J van der Ploeg-van Schip; Karien C Wiesmeijer; Terhi Riuttamäki; Krista E van Meijgaarden; John S Spencer; Hans J Tanke; Tom H M Ottenhoff; Annemieke Geluk
Journal:  Clin Biochem       Date:  2011-07-06       Impact factor: 3.281

Review 6.  Chemokines shape the immune responses to tuberculosis.

Authors:  Samantha R Slight; Shabaana A Khader
Journal:  Cytokine Growth Factor Rev       Date:  2012-11-16       Impact factor: 7.638

7.  IP-10 and MIG are compartmentalized at the site of disease during pleural and meningeal tuberculosis and are decreased after antituberculosis treatment.

Authors:  Qianting Yang; Yi Cai; Wei Zhao; Fan Wu; Mingxia Zhang; Kai Luo; Yan Zhang; Haiying Liu; Boping Zhou; Hardy Kornfeld; Xinchun Chen
Journal:  Clin Vaccine Immunol       Date:  2014-10-01

8.  MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.

Authors:  Susanna J Dunachie; Tamara Berthoud; Sheila M Keating; Adrian V S Hill; Helen A Fletcher
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

9.  Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.

Authors:  Denise Morais da Fonseca; Celio Lopes Silva; Pryscilla Fanini Wowk; Marina Oliveira E Paula; Simone Gusmão Ramos; Cynthia Horn; Gilles Marchal; Vânia Luiza Deperon Bonato
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

10.  CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis.

Authors:  Zahra Hasan; Jacqueline M Cliff; Hazel M Dockrell; Bushra Jamil; Muhammad Irfan; Mussarat Ashraf; Rabia Hussain
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.